AxoGen, Inc. revised revenue guidance for the full year of 2023. The company now expects full-year 2023 revenue to be at the high end of the $154 million to $159 million guidance range provided earlier in the year. This represents annual growth of approximately 15%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.98 USD | +1.87% | +1.70% | -12.45% |
02/05 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
02/05 | Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.45% | 257M | |
+8.88% | 219B | |
+8.68% | 185B | |
+14.25% | 135B | |
+28.18% | 107B | |
+14.65% | 51.28B | |
+4.48% | 51.01B | |
+4.39% | 41.85B | |
+7.00% | 37.02B | |
+26.06% | 31.27B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen, Inc. Revises Revenue Guidance for the Full Year of 2023